Person: Dr Pierre Meulien

Dr Pierre Meulien, former president and CEO, Genome Canada

Turning genomic data into insight takes investment
By Dr Pierre Meulien

The sequencing of human, animal and plant DNA is happening more quickly and in more incredible volumes than we ever could have imagined, producing some amazing comparisons.

Dr Pierre Meulien

Dr Pierre Meulien has stepped down as president and CEO of Genome Canada to become executive director of the Innovative Medicines Initiative (IMI). Meulien departed Genome Canada July 17th and takes up his IMI duties in Brussels in mid-September to lead the second phase of the €3.3-billion drug research program between the European Union and…

Maria Aubrey

Maria Aubrey has been appointed VP business and professional services at the National Research Council. Most recently an operations/program management consultant, Aubrey was senior VP operations at Sustainable Development Technology Canada for more than seven years. She has also held numerous operations positions in the private sector including XIA Systems Corp, Technologies, and more than…

Guy Levesque, 2015

Guy Levesque has been promoted to VP programs and planning at the Canada Foundation for Innovation, Previously director of programs, Levesque has worked primarily at the CFI and NSERC since 1998. He holds a BSc. and MSc in earth sciences and a BEd from the Univ of Ottawa….

Dr Pierre Meulien

Dr Pierre Meulien has been appointed president and CEO of Genome Canada, replacing interim president and CEO Dale Patterson and filling a gap that was created by the abrupt departure of Dr Martin Godbout last year (R$, October 26/09). Meulien comes from Genome BC where he served as chief scientific officer for 3.5 years. He…

Dr Robert Crawhall

Dr Robert Crawhall has been appointed VP operations at Precarn Inc as the organization makes a bid to expand its scope to include all information and communications technologies (ICT) (R$, October 14/10). Crawhall comes to Precarn from NanoQuébec where he served as CEO since July/08. He previously led the National Capital Institute of Telecommunications and…

Dr Anita McGahan

Dr Anita McGahan has been appointed to the newly created position of associate dean of research at the Rotman School of Management. McGahan will be responsible for the school’s PhD program and oversee its research activities including its Business Information Centre. She holds an MA and PhD in business economics from Harvard Graduate School of…

Simon Kennedy

Simon Kennedy has been appointed senior associate DM at Industry Canada with responsibility for the science and innovation and strategic policy sectors. Kennedy has extensive experience at the Privy Council Office, most recently as deputy secretary to the Cabinet (plans and consultation)….

Carl Roy

Carl Roy has been appointed president and CEO of bioLytical Laboratories, a Vancouver-based developer of rapid HIV diagnostic products. Roy comes to bioLytical from Perceptronix Medical Inc, where he helped shift the company’s strategic focus from R&D to product commercialization in less than one year. He is also former president and CEO of Providence Health…

Francoise Gavin

Francoise Gavin has been appointed a partner and chief financial officer of MSBI Capital Inc, a seed and early-stage venture capital fund started with $11 million from Valorisation-Recherche Québec (R$, September 28/04). Gavin comes to MSBI from Solidarity Fund QFL where he managed its $250-million external technology fund portfolio. He has also held senior positions…